Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

age clinical studies," said Mr. Swisher.

Actions taken today will allow the company to direct most of its resources into the late-stage development of voreloxin. Sunesis expects this realignment of personnel and programs to reduce annual operating expenses by more than $15 million, thus enabling increased investment into such development. Current burn rate guidance for the second half of 2008 is in the range of $12-15 million, including payment of severance and other restructuring charges.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication- dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Hemoglobin A1C levels ... with Type 2 diabetes, while modest improvements in ... outcomes and can lead to substantial healthcare cost ... International Society for Pharmacoeconomics and Outcomes Research (ISPOR) ... studies, sponsored by Valeritas, makers of the V-Go ...
(Date:5/22/2013)...   Life Line Screening  (LLS), a leading ... creation of a unique partnership with MCM Solutions ... is a population health management organization. LLS will provide ... These important expanded services will help MCM and its ... reduces cost of care when individuals are able to ...
(Date:5/22/2013)... May 22, 2013  Avanir Pharmaceuticals, Inc. (NASDAQ: ... overview of the company at the following conferences. ... Presentation date: Wednesday May 29, 2013 , Presentation time: ... Healthcare Conference , Presentation date: Wednesday June 5, 2013 ... A live webcast and 30-day archive of ...
Breaking Medicine Technology:Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2
... Columbia Laboratories, Inc. (Nasdaq: CBRX ) and Watson ... the U.S. Food and Drug Administration (FDA) has accepted for ... (progesterone gel) for the reduction of risk of preterm birth ... of pregnancy. The acceptance of the NDA for filing means ...
... Calif., June 27, 2011 Advanced Sterilization ... an innovative infection prevention technology – GLOSAIR™ Healthcare ... thorough disinfection of hospital rooms and operating suites ... infection-causing pathogens. There is a growing scientific consensus ...
Cached Medicine Technology:Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA 2Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA 3Columbia Laboratories' NDA for PROCHIEVE® Vaginal Progesterone Gel Accepted for Filing by FDA 4ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 2ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 3ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 4ASP Launches GLOSAIR™ Healthcare Environmental Decontamination at the 2011 APIC Conference to Protect Against the Risk of Deadly Infections in Healthcare Facilities 5
(Date:5/23/2013)... 23, 2013 Kitchen on Fire ... classes, the most advanced culinary technique series currently offered ... with the knowledge of how to purchase, butcher and ... health benefits of organic, local ingredients. The new Intermediate ... six hours each. The next series begins on Sunday, ...
(Date:5/23/2013)... Get ready to sweat. , Automatic Body ... conjunction with the Nutrié California Kick Off ... will get the chance to work out with celebrity ... Dr. Oz Show, and The Dr. Phil Weight Loss ... undefeated UFC heavy-weight contender Daniel Cormier at Chukchansi Park ...
(Date:5/23/2013)... Daimer Industries, Inc.®, the undisputed leader ... , including outstanding car wash equipment and ... other popular cleaning machines with many satisfied customers ... offering the Super Max™ 7000, an electric-powered, tri-mode ... of cleaning applications, such as maintaining wheelchairs. ...
(Date:5/22/2013)... Pleasant Prairie, WI (PRWEB) May 23, 2013 ... company , introduced a new feature to its ... example from the agency’s client portfolio through an immersive, ... gives clients and prospective customers the ability to virtually ... Medical, a developer of medical technologies and services. Users ...
(Date:5/22/2013)... of Lady Niguma was created by a female yogi (‘yogini’) from ... oldest yoga found in written form (in a book made from ... Indian master and yogi Naropa, and the yoga she created is ... , Lady Niguma taught the practice to her student Kyungpo ... to the second Dalai Lama, Gendun Gyatso. While researching rare texts ...
Breaking Medicine News(10 mins):Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 2Health News:Kitchen on Fire Launches Intermediate Cooking Series, Advancing the Culinary Skills of Experienced Home Chefs 3Health News:Kim Lyons, Gunter Schlierkamp, & Daniel Cormier To Host Fresno Charity Workout 2Health News:Kim Lyons, Gunter Schlierkamp, & Daniel Cormier To Host Fresno Charity Workout 3Health News:Commercial Pressure Washer Debuted By Daimer Industries For Wheelchair Cleaning 2Health News:Commercial Pressure Washer Debuted By Daimer Industries For Wheelchair Cleaning 3Health News:Commercial Pressure Washer Debuted By Daimer Industries For Wheelchair Cleaning 4Health News:Catalyst Exhibits Debuts 360 Degree Virtual Tour of St. Jude Medical Trade Show Booth 2Health News:Popular Yoga DVD, Lady Niguma Yoga Released for Sale Online 2Health News:Popular Yoga DVD, Lady Niguma Yoga Released for Sale Online 3
... main ingredient of turmeric that gives curry its mustard-yellow ... plant, curcumin is a member of the ginger family//. ... is widely prescribed in Indian medicine as a potent ... cough and sinusitis. ,Various studies have examined ...
... Administration is planning to approve the first home based rapid HIV ... within 20 minutes of the test without any physician or clinician ... doctors and clinics, which may go public after FDA approval. This ... HIV negative and presence of two lines implies infection and the ...
... inflammatory disorder of the gastrointestinal tract. Although ... many experimental and clinical observations have suggested ... ,In genetically susceptible individuals, tissue ... regulatory constraints on the mucosal immune responsiveness ...
... In a study conducted on factors that predispose to drinking habits, ... like lie, steal or skip school is what encourages alcohol consumption ... ,The study is the first of it’s kind to ... assumption that a family history of alcohol dependency predisposes to the ...
... that woks by reducing the sebum secretion. Research done on ... it can cause birth defects//. In view of the potential ... manufacturers developed a voluntary pregnancy prevention program (PPP) in 1988 ... , ,It was soon placed by the SMART program ...
... lagging in innovation, as shown by the market share ... and hospital markets. Reports from various sources prove that ... of pharmaceuticals and hospital care//. , ,Europe has ... competitive position of its biopharmaceutical enterprises. The policy is ...
Cached Medicine News:Health News:Curcumin found to halt spread of breast cancer in mice 2Health News:Home Based Rapid HIV Test Kit to be approved by US – OraQuick Test Ki 2Health News:Bifidogenic Growth Stimulator: A Non-Toxic Way To Treat Ulcerative Colitis 2Health News:Birth Defects Caused By Acne Medication Can Be Minimized By Voluntary Pregnancy Prevention 2
... design allows "Four gels in one tank" electrophoresis. ... run 200 samples or more in one compact ... gels. To ensure even migration, the electrode height ... being run. Ideal for high throughput procedures, an ...
... tanks come with turn and cast gel ... pouring as simple as possible. , ... your application. Avaialble in a variety of ... gel size right up to the 20 ...
... UniPhor units can be used for: ... and non denaturing SDS-PAGE gels IEF ... Z64,075 1) Preparative Protein and Peptide ... gels IEF in Agarose Ampholyte Gels ...
... Horizontal Gel System provides a compact format ... DNA fragments, PCR products and synthetic oligonucleotides, ... The Mini Horizontal Unit has gel bed ... The gel bed is UV transparent. Adjustable ...
Medicine Products: